vs
ANI PHARMACEUTICALS INC（ANIP）与Prestige Consumer Healthcare Inc.（PBH）财务数据对比。点击上方公司名可切换其他公司
Prestige Consumer Healthcare Inc.的季度营收约是ANI PHARMACEUTICALS INC的1.1倍（$283.4M vs $247.1M），Prestige Consumer Healthcare Inc.净利率更高（16.5% vs 11.1%，领先5.3%），ANI PHARMACEUTICALS INC同比增速更快（29.6% vs -2.4%），Prestige Consumer Healthcare Inc.自由现金流更多（$75.3M vs $29.1M），过去两年ANI PHARMACEUTICALS INC的营收复合增速更高（34.1% vs 1.2%）
ANI制药是一家总部位于美国的特种制药企业，专注于研发、生产和销售仿制药及品牌处方药，核心产品覆盖皮肤科、肿瘤、中枢神经系统治疗、抗感染等领域，主要服务美国境内的医疗机构、零售药房和患者群体。
Prestige Consumer Healthcare Inc.是一家美国企业，主营非处方健康护理产品及家用清洁产品的营销与分销业务。该公司于1996年由Medtech Products、Prestige Brands International及Spic and Span三家公司合并成立，总部位于纽约州塔里敦，在弗吉尼亚州林奇堡设有生产工厂。
ANIP vs PBH — 直观对比
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $247.1M | $283.4M |
| 净利润 | $27.5M | $46.7M |
| 毛利率 | — | 55.5% |
| 营业利润率 | 14.1% | 29.1% |
| 净利率 | 11.1% | 16.5% |
| 营收同比 | 29.6% | -2.4% |
| 净利润同比 | 367.5% | -23.5% |
| 每股收益（稀释后） | $1.14 | $0.97 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $247.1M | $283.4M | ||
| Q3 25 | $227.8M | $274.1M | ||
| Q2 25 | $211.4M | $249.5M | ||
| Q1 25 | $197.1M | $296.5M | ||
| Q4 24 | $190.6M | $290.3M | ||
| Q3 24 | $148.3M | $283.8M | ||
| Q2 24 | $138.0M | $267.1M | ||
| Q1 24 | $137.4M | $277.0M |
| Q4 25 | $27.5M | $46.7M | ||
| Q3 25 | $26.6M | $42.2M | ||
| Q2 25 | $8.5M | $47.5M | ||
| Q1 25 | $15.7M | $50.1M | ||
| Q4 24 | $-10.3M | $61.0M | ||
| Q3 24 | $-24.2M | $54.4M | ||
| Q2 24 | $-2.3M | $49.1M | ||
| Q1 24 | $18.2M | $49.5M |
| Q4 25 | — | 55.5% | ||
| Q3 25 | — | 55.3% | ||
| Q2 25 | — | 56.2% | ||
| Q1 25 | — | 57.3% | ||
| Q4 24 | — | 55.5% | ||
| Q3 24 | — | 55.5% | ||
| Q2 24 | — | 54.7% | ||
| Q1 24 | — | 54.8% |
| Q4 25 | 14.1% | 29.1% | ||
| Q3 25 | 15.9% | 29.1% | ||
| Q2 25 | 6.6% | 28.8% | ||
| Q1 25 | 13.3% | 29.8% | ||
| Q4 24 | -2.3% | 31.7% | ||
| Q3 24 | -13.8% | 29.7% | ||
| Q2 24 | 3.7% | 27.0% | ||
| Q1 24 | 14.8% | 29.7% |
| Q4 25 | 11.1% | 16.5% | ||
| Q3 25 | 11.7% | 15.4% | ||
| Q2 25 | 4.0% | 19.0% | ||
| Q1 25 | 8.0% | 16.9% | ||
| Q4 24 | -5.4% | 21.0% | ||
| Q3 24 | -16.3% | 19.2% | ||
| Q2 24 | -1.7% | 18.4% | ||
| Q1 24 | 13.2% | 17.9% |
| Q4 25 | $1.14 | $0.97 | ||
| Q3 25 | $1.13 | $0.86 | ||
| Q2 25 | $0.36 | $0.95 | ||
| Q1 25 | $0.69 | $1.00 | ||
| Q4 24 | $-0.45 | $1.22 | ||
| Q3 24 | $-1.27 | $1.09 | ||
| Q2 24 | $-0.14 | $0.98 | ||
| Q1 24 | $0.82 | $0.98 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $285.6M | $62.4M |
| 总债务越低越好 | — | $1.0B |
| 股东权益账面价值 | $540.7M | $1.8B |
| 总资产 | $1.4B | $3.5B |
| 负债/权益比越低杠杆越低 | — | 0.56× |
8季度趋势，按日历期对齐
| Q4 25 | $285.6M | $62.4M | ||
| Q3 25 | $262.6M | $119.1M | ||
| Q2 25 | $217.8M | $139.5M | ||
| Q1 25 | $149.8M | $97.9M | ||
| Q4 24 | $144.9M | $50.9M | ||
| Q3 24 | $145.0M | $51.5M | ||
| Q2 24 | $240.1M | $34.3M | ||
| Q1 24 | $228.6M | $46.5M |
| Q4 25 | — | $1.0B | ||
| Q3 25 | — | $993.1M | ||
| Q2 25 | — | $992.7M | ||
| Q1 25 | — | $992.4M | ||
| Q4 24 | — | $992.0M | ||
| Q3 24 | — | $1.1B | ||
| Q2 24 | — | $1.1B | ||
| Q1 24 | — | $1.1B |
| Q4 25 | $540.7M | $1.8B | ||
| Q3 25 | $505.8M | $1.8B | ||
| Q2 25 | $436.8M | $1.9B | ||
| Q1 25 | $418.6M | $1.8B | ||
| Q4 24 | $403.7M | $1.8B | ||
| Q3 24 | $405.9M | $1.7B | ||
| Q2 24 | $455.8M | $1.7B | ||
| Q1 24 | $452.0M | $1.7B |
| Q4 25 | $1.4B | $3.5B | ||
| Q3 25 | $1.4B | $3.4B | ||
| Q2 25 | $1.3B | $3.4B | ||
| Q1 25 | $1.3B | $3.4B | ||
| Q4 24 | $1.3B | $3.3B | ||
| Q3 24 | $1.3B | $3.3B | ||
| Q2 24 | $920.8M | $3.3B | ||
| Q1 24 | $914.5M | $3.3B |
| Q4 25 | — | 0.56× | ||
| Q3 25 | — | 0.54× | ||
| Q2 25 | — | 0.54× | ||
| Q1 25 | — | 0.54× | ||
| Q4 24 | — | 0.55× | ||
| Q3 24 | — | 0.61× | ||
| Q2 24 | — | 0.65× | ||
| Q1 24 | — | 0.68× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $30.4M | $78.3M |
| 自由现金流经营现金流 - 资本支出 | $29.1M | $75.3M |
| 自由现金流率自由现金流/营收 | 11.8% | 26.6% |
| 资本支出强度资本支出/营收 | 0.5% | 1.1% |
| 现金转化率经营现金流/净利润 | 1.10× | 1.68× |
| 过去12个月自由现金流最近4个季度 | $171.4M | $267.2M |
8季度趋势，按日历期对齐
| Q4 25 | $30.4M | $78.3M | ||
| Q3 25 | $44.1M | $57.5M | ||
| Q2 25 | $75.8M | $79.0M | ||
| Q1 25 | $35.0M | $61.8M | ||
| Q4 24 | $15.9M | $65.1M | ||
| Q3 24 | $12.5M | $69.8M | ||
| Q2 24 | $17.4M | $54.8M | ||
| Q1 24 | $18.3M | $66.9M |
| Q4 25 | $29.1M | $75.3M | ||
| Q3 25 | $38.0M | $55.4M | ||
| Q2 25 | $71.8M | $78.2M | ||
| Q1 25 | $32.5M | $58.4M | ||
| Q4 24 | $13.5M | $63.5M | ||
| Q3 24 | $7.7M | $67.8M | ||
| Q2 24 | $13.0M | $53.6M | ||
| Q1 24 | $13.7M | $63.8M |
| Q4 25 | 11.8% | 26.6% | ||
| Q3 25 | 16.7% | 20.2% | ||
| Q2 25 | 34.0% | 31.3% | ||
| Q1 25 | 16.5% | 19.7% | ||
| Q4 24 | 7.1% | 21.9% | ||
| Q3 24 | 5.2% | 23.9% | ||
| Q2 24 | 9.4% | 20.1% | ||
| Q1 24 | 10.0% | 23.0% |
| Q4 25 | 0.5% | 1.1% | ||
| Q3 25 | 2.7% | 0.8% | ||
| Q2 25 | 1.9% | 0.3% | ||
| Q1 25 | 1.3% | 1.2% | ||
| Q4 24 | 1.3% | 0.5% | ||
| Q3 24 | 3.2% | 0.7% | ||
| Q2 24 | 3.2% | 0.4% | ||
| Q1 24 | 3.3% | 1.1% |
| Q4 25 | 1.10× | 1.68× | ||
| Q3 25 | 1.66× | 1.36× | ||
| Q2 25 | 8.87× | 1.66× | ||
| Q1 25 | 2.23× | 1.23× | ||
| Q4 24 | — | 1.07× | ||
| Q3 24 | — | 1.28× | ||
| Q2 24 | — | 1.12× | ||
| Q1 24 | 1.00× | 1.35× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
PBH
| Womens Health | $51.8M | 18% |
| International OTC Healthcare | $47.7M | 17% |
| Gastrointestinal | $44.2M | 16% |
| Eye And Ear Care | $35.2M | 12% |
| Dermatologicals | $27.6M | 10% |
| Analgesics | $26.7M | 9% |
| Oral Care | $23.5M | 8% |
| Cough And Cold | $23.0M | 8% |
| Other Otc | $3.6M | 1% |
